Boehringer's HIV treatment effective in young patients

08/5/2008 | Bloomberg · Forbes

A two-year trial found that Aptivus, a protease inhibitor from Boehringer Ingelheim, was safe and effective in HIV-infected children and adolescents who took other treatments for the condition. The study, which covered 26 sites in the U.S., Europe and Latin America, showed that patients who received a combination of Aptivus and ritonavir, another HIV drug, had decreased virus levels.

View Full Article in:

Bloomberg · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC